Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Supportive and palliative care

2106 - Training oncologists and preparing patients for shared decision making about palliative systemic treatment: results from the randomized controlled CHOICE study


21 Oct 2018


Proffered paper session - Supportive and palliative care


Career Development;  Cancer Research;  End-of-Life Care;  Patient Education and Advocacy

Tumour Site


Hanneke van Laarhoven


Annals of Oncology (2018) 29 (suppl_8): viii548-viii556. 10.1093/annonc/mdy295


H.W.M. van Laarhoven1, I. Henselmans2, P. van Maarschalkerweerd3, H. de Haes3, D.W. Sommeijer4, P.B. Ottevanger5, H. Fiebrich6, S.E. Dohmen7, G.M. Creemers8, F.Y.F.L. De Vos9, E.M. Smets10

Author affiliations

  • 1 Medical Oncology, Academic Medical Center, University of Amsterdam, 1100 DD - Amsterdam/NL
  • 2 Medical Psychology, Academic Medical Center, 1105AZ - Amsterdam/NL
  • 3 Medical Psychology, Academic Medical Center, Amsterdam/NL
  • 4 Medical Oncology, Flevoziekenhuis, Almere/NL
  • 5 Medical Oncology, Radboud University Medical Centre Nijmegen, 6500 HB - Nijmegen/NL
  • 6 Medical Oncology, Isalaklinieken, Zwolle/NL
  • 7 Medical Oncology, Bovenij Hospital, 1034 CS - Amsterdam/NL
  • 8 Medical Oncology, Catharina Hospital Eindhoven, 5602 ZA - Eindhoven/NL
  • 9 Medical Oncology, University Hospital Utrecht, 3508 GA - Utrecht/NL
  • 10 Medical Psychology, Academic Medical Center (AMC), 1105AZ - Amsterdam/NL


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 2106


Systematic treatment for advanced cancer offers uncertain and often limited benefits whilst the burden can be high. Hence, treatment decisions require Shared Decision Making (SDM). We examined the separate and combined effect of oncologist training and a patient communication aid on SDM in consultations about palliative systemic treatment.


A multi-center RCT with four parallel arms was conducted (NTR 5489). To attain a power of 80%, we included 31 medical oncologists and 194 of their patients with advanced cancer with a median life expectancy of < 12 months. Oncologists were randomized to receive training or not; patients were randomized to receive a patient communication aid or not. The oncologist training consisted of a reader, two group sessions, a booster feedback session and a consultation room tool. The patient communication aid consisted of a question prompt list and a value clarification exercise. Either an initial consultation about the start of systemic treatment or an evaluative consultation about (dis)continuation was audio-recorded for each patient. The primary outcome was observed SDM (OPTION12), rated by blinded assessors. Intervention effects were investigated with multilevel analysis.


Audio-recorded consultations of 187 patients and 27 oncologists were available for analysis. The oncologist training had a large effect on observed SDM among patients who did not receive a communication aid (d = 1.4). The patient communication aid did not have an effect on SDM among untrained oncologists (d = 0.03). The effect of the combination of training and communication aid did not exceed the single effect of training (Mtraining_aid=49.83; Mtraining_no aid=49.49; Mno training_aid=29.88; Mno training_no aid=29.50).


Training medical oncologists in SDM about palliative systemic treatment improved observed SDM in clinical encounters. A patient communication aid preparing patients for SDM did not add to that effect. Additional analysis should examine the effects of both interventions on secondary outcomes, such as patient satisfaction and treatment decisions.

Clinical trial identification

Netherlands Trial Registry 5489 (prospective, Sep 15 2015).

Legal entity responsible for the study

Department of Medical Psychology, Academic Medical Center, Amsterdam.


Dutch Cancer Society.

Editorial Acknowledgement


H.W.M. van Laarhoven: Consultant or advisory role: BMS, Lilly and Nordic Pharma; Research funding: Bayer, BMS, Celgene, Janssen, Lilly, Nordic Pharma, Philips, Roche. F.Y.F.L. De Vos: Research funding: Novartis, AbbVie en BioClin. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.